对“帕罗伐他汀可减少青少年 FOP 小鼠的异位骨化，但表现出明显的骨骼毒性”一文的评论作出回应。
Response to comment on 'Palovarotene reduces heterotopic ossification in juvenile FOP mice but exhibits pronounced skeletal toxicity'.
机构信息
Department of Molecular and Cell Biology, University of Connecticut, Storrs, United States.
出版信息
Elife. 2019 Jan 30;8:e43928. doi: 10.7554/eLife.43928.
Abstract
We respond to concerns expressed by Pacifici and Shore (2019) about a recent paper (Lees-Shepard and Goldhamer, 2018a) in which we reported that the drug palovarotene can have severe side effects in a mouse model of fibrodysplasia ossificans progressiva.
摘要
我们对 Pacifici 和 Shore（2019）对我们最近一篇论文（Lees-Shepard 和 Goldhamer，2018a）提出的担忧做出回应。在这篇论文中，我们报告了药物 palovarotene 在纤维发育不良性骨化进展的小鼠模型中可能产生严重的副作用。
相似文献
1
Response to comment on 'Palovarotene reduces heterotopic ossification in juvenile FOP mice but exhibits pronounced skeletal toxicity'.对“帕罗伐他汀可减少青少年 FOP 小鼠的异位骨化，但表现出明显的骨骼毒性”一文的评论作出回应。
Elife. 2019 Jan 30;8:e43928. doi: 10.7554/eLife.43928.
2
Comment on 'Palovarotene reduces heterotopic ossification in juvenile FOP mice but exhibits pronounced skeletal toxicity'.评“帕罗伐他汀可减少青少年 FOP 小鼠的异位骨化，但表现出明显的骨骼毒性”。
Elife. 2019 Jan 30;8:e43173. doi: 10.7554/eLife.43173.
3
Palovarotene Inhibits Heterotopic Ossification and Maintains Limb Mobility and Growth in Mice With the Human ACVR1(R206H) Fibrodysplasia Ossificans Progressiva (FOP) Mutation.帕罗维罗汀可抑制携带人类ACVR1（R206H）突变的进行性骨化性纤维发育不良（FOP）小鼠的异位骨化，并维持肢体活动能力和生长。
J Bone Miner Res. 2016 Sep;31(9):1666-75. doi: 10.1002/jbmr.2820. Epub 2016 Mar 12.
4
Palovarotene reduces heterotopic ossification in juvenile FOP mice but exhibits pronounced skeletal toxicity.帕拉罗伐醇可减少幼年 FOP 小鼠的异位骨化，但表现出明显的骨骼毒性。
Elife. 2018 Sep 18;7:e40814. doi: 10.7554/eLife.40814.
5
Surgical management of bilateral hip fractures in a patient with fibrodysplasia ossificans progressiva treated with the RAR-γ agonist palovarotene: a case report.使用维甲酸受体γ激动剂帕罗西汀治疗进行性骨化性纤维发育不良患者双侧髋部骨折的手术管理：一例报告
BMC Musculoskelet Disord. 2020 Apr 3;21(1):204. doi: 10.1186/s12891-020-03240-2.
6
Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP): Results of a Randomized, Placebo-Controlled, Double-Blind Phase 2 Trial.帕罗伐罗肽治疗进行性骨化性纤维发育不良（FOP）：一项随机、安慰剂对照、双盲 2 期临床试验的结果。
J Bone Miner Res. 2022 Oct;37(10):1891-1902. doi: 10.1002/jbmr.4655. Epub 2022 Aug 17.
7
Palovarotene: First Approval.帕罗维罗替治疗法：首次批准。
Drugs. 2022 Apr;82(6):711-716. doi: 10.1007/s40265-022-01709-z.
8
Reduction of New Heterotopic Ossification (HO) in the Open-Label, Phase 3 MOVE Trial of Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP).在帕罗西汀治疗进行性骨化性纤维发育不良（FOP）的开放标签3期MOVE试验中减少新的异位骨化（HO）。
J Bone Miner Res. 2023 Mar;38(3):381-394. doi: 10.1002/jbmr.4762. Epub 2023 Jan 25.
9
Cartilage-derived retinoic acid-sensitive protein (CD-RAP): A stage-specific biomarker of heterotopic endochondral ossification (HEO) in fibrodysplasia ossificans progressiva (FOP).软骨源性维甲酸敏感蛋白 (CD-RAP)：成纤维细胞性骨化发育不良进展期 (FOP) 异位软骨内骨化 (HEO) 的阶段特异性生物标志物。
Bone. 2018 Apr;109:153-157. doi: 10.1016/j.bone.2017.09.016. Epub 2017 Sep 28.
10
Therapeutic advances for blocking heterotopic ossification in fibrodysplasia ossificans progressiva.纤维发育不良性骨化性纤维发育不良中抑制异位骨化的治疗进展。
Br J Clin Pharmacol. 2019 Jun;85(6):1180-1187. doi: 10.1111/bcp.13823. Epub 2019 Jan 6.
引用本文的文献
1
Sex as a Critical Variable in Basic and Pre-Clinical Studies of Fibrodysplasia Ossificans Progressiva.性别的基础和临床前研究中的纤维发育不良性骨化进展的关键变量。
Biomolecules. 2024 Feb 1;14(2):177. doi: 10.3390/biom14020177.
2
Overexpression of Wild-Type ACVR1 in Fibrodysplasia Ossificans Progressiva Mice Rescues Perinatal Lethality and Inhibits Heterotopic Ossification.野生型 ACVR1 在进行性骨化性纤维发育不良小鼠中的过表达可挽救围产期致死性并抑制异位骨化。
J Bone Miner Res. 2022 Nov;37(11):2077-2093. doi: 10.1002/jbmr.4617. Epub 2022 Jul 3.
3
Challenges and Opportunities for Drug Repositioning in Fibrodysplasia Ossificans Progressiva.进行性骨化性纤维发育不良中药物重新定位的挑战与机遇
Biomedicines. 2021 Feb 19;9(2):213. doi: 10.3390/biomedicines9020213.
本文引用的文献
1
Comment on 'Palovarotene reduces heterotopic ossification in juvenile FOP mice but exhibits pronounced skeletal toxicity'.评“帕罗伐他汀可减少青少年 FOP 小鼠的异位骨化，但表现出明显的骨骼毒性”。
Elife. 2019 Jan 30;8:e43173. doi: 10.7554/eLife.43173.
2
Palovarotene reduces heterotopic ossification in juvenile FOP mice but exhibits pronounced skeletal toxicity.帕拉罗伐醇可减少幼年 FOP 小鼠的异位骨化，但表现出明显的骨骼毒性。
Elife. 2018 Sep 18;7:e40814. doi: 10.7554/eLife.40814.
3
Stem cells and heterotopic ossification: Lessons from animal models.干细胞与异位骨化：动物模型的启示。
Bone. 2018 Apr;109:178-186. doi: 10.1016/j.bone.2018.01.029. Epub 2018 Jan 31.
4
Activin-dependent signaling in fibro/adipogenic progenitors causes fibrodysplasia ossificans progressiva.激活素依赖性信号在纤维/脂肪祖细胞中引起进行性骨化性纤维发育不良。
Nat Commun. 2018 Feb 2;9(1):471. doi: 10.1038/s41467-018-02872-2.
5
Palovarotene Inhibits Heterotopic Ossification and Maintains Limb Mobility and Growth in Mice With the Human ACVR1(R206H) Fibrodysplasia Ossificans Progressiva (FOP) Mutation.帕罗维罗汀可抑制携带人类ACVR1（R206H）突变的进行性骨化性纤维发育不良（FOP）小鼠的异位骨化，并维持肢体活动能力和生长。
J Bone Miner Res. 2016 Sep;31(9):1666-75. doi: 10.1002/jbmr.2820. Epub 2016 Mar 12.
6
Fibrodysplasia ossificans progressiva: mechanisms and models of skeletal metamorphosis.进行性骨化性纤维发育不良：骨骼变形的机制和模型。
Dis Model Mech. 2012 Nov;5(6):756-62. doi: 10.1242/dmm.010280.
7
An Acvr1 R206H knock-in mouse has fibrodysplasia ossificans progressiva.一种 Acvr1 R206H 点突变的小鼠患有进行性骨化性纤维发育不良。
J Bone Miner Res. 2012 Aug;27(8):1746-56. doi: 10.1002/jbmr.1637.
8
Evolutionary divergence of platelet-derived growth factor alpha receptor signaling mechanisms.血小板衍生生长因子α受体信号传导机制的进化分歧
Mol Cell Biol. 2003 Jun;23(11):4013-25. doi: 10.1128/MCB.23.11.4013-4025.2003.
9
Platelet-derived growth factor A modulates limb chondrogenesis both in vivo and in vitro.血小板衍生生长因子A在体内和体外均调节肢体软骨形成。
Mech Dev. 2000 Jun;94(1-2):13-24. doi: 10.1016/s0925-4773(00)00321-x.
10
Platelet-derived growth factor-A and its receptor are expressed in separate, but adjacent cell layers of the mouse embryo.血小板衍生生长因子-A及其受体在小鼠胚胎中分别表达于相邻但不同的细胞层。
Development. 1992 Aug;115(4):1045-58. doi: 10.1242/dev.115.4.1045.
Zotero 插件